Concetta Barone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6912743/publications.pdf

Version: 2024-02-01

623734 552781 37 720 14 26 h-index citations g-index papers 38 38 38 1117 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Methionine synthase (MTR) 2756 (A → G) polymorphism, double heterozygosity methionine synthase 2 AG/methionine synthase reductase (MTRR) 66 AG, and elevated homocysteinemia are three risk factors for having a child with Down syndrome. American Journal of Medical Genetics, Part A, 2003, 121A, 219-224.	2756 1.2	124
2	The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant. European Journal of Human Genetics, 2016, 24, 652-659.	2.8	108
3	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer's and Dementia, 2016, 12, 1132-1148.	0.8	75
4	An Updated Survey on Skin Conditions in Down Syndrome. Dermatology, 2002, 205, 234-238.	2.1	72
5	Homocysteine and related genetic polymorphisms in Down's syndrome IQ. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 706-709.	1.9	42
6	Effects of repetitive transcranial magnetic stimulation in performing eye–hand integration tasks: Four preliminary studies with children showing low-functioning autism. Autism, 2014, 18, 638-650.	4.1	30
7	The MTRR 66A>G polymorphism and maternal risk of birth of a child with Down syndrome in Caucasian women: a case–control study and a meta-analysis. Molecular Biology Reports, 2014, 41, 5571-5583.	2.3	23
8	A prevalence study of celiac disease in persons with Down syndrome residing in the United States of America. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 953-956.	1.5	22
9	Alopecia areata in Down syndrome: a clinical evaluation. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 769-770.	2.4	21
10	Familial 1.1ÂMb deletion in chromosome Xq22.1 associated with mental retardation and behavioural disorders in female patients. European Journal of Medical Genetics, 2010, 53, 113-116.	1.3	20
11	Prevalence of atopic dermatitis in patients with Down syndrome: A clinical survey. Journal of the American Academy of Dermatology, 1997, 36, 1019-1021.	1.2	19
12	3q29 microdeletion syndrome: Cognitive and behavioral phenotype in four patients. American Journal of Medical Genetics, Part A, 2013, 161, 3018-3022.	1.2	19
13	Allele $\hat{l}\mu 4$ of apolipoprotein E gene is less frequent in Down syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. Neuroscience Letters, 2001, 306, 129-131.	2.1	18
14	The MTR 2756A>G polymorphism and maternal risk of birth of a child with Down syndrome: a case–control study and a meta-analysis. Molecular Biology Reports, 2013, 40, 6913-6925.	2.3	17
15	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. European Journal of Pharmacology, 2017, 817, 7-19.	3.5	15
16	Duplex scanning of neck vessels: need for extending the consensus on indications. Neurological Sciences, 2002, 22, 437-441.	1.9	10
17	Is there a relationship between zinc and the peculiar comorbidities of Down syndrome?. Down Syndrome Research and Practice, 2002, 8, 25-28.	0.3	10
18	Mitochondrial mRNA expression in fibroblasts of Down syndrome subjects. Human Cell, 2018, 31, 179-181.	2.7	8

#	Article	IF	Citations
19	Three new patients with dup(17)(p11.2p11.2) without autism. Clinical Genetics, 2008, 73, 294-296.	2.0	7
20	KIF21A mRNA expression in patients with Down syndrome. Neurological Sciences, 2013, 34, 569-571.	1.9	7
21	Differential expression of PARP1 mRNA in leucocytes of patients with Down's syndrome. Journal of Genetics, 2011, 90, 469-472.	0.7	6
22	Pericentrin expression in Down's syndrome. Neurological Sciences, 2013, 34, 2023-2025.	1.9	5
23	Killer-specific secretory (Ksp37) gene expression in subjects with Down's syndrome. Neurological Sciences, 2016, 37, 793-795.	1.9	5
24	Gene expression profiling and qRT-PCR expression of RRP1B, PCNT, KIF21A and ADRB2 in leucocytes of Down's syndrome subjects. Journal of Genetics, 2012, 91, e18-23.	0.7	5
25	Gene expression profiling and qRT-PCR expression of RRP1B, PCNT, KIF21A and ADRB2 in leucocytes of Down's syndrome subjects. Journal of Genetics, 2014, 93, 18-23.	0.7	4
26	NF-kB1 gene expression in Down syndrome patients. Neurological Sciences, 2015, 36, 1065-1066.	1.9	4
27	Long non-coding RNA GAS5 expression in patients with Down syndrome. International Journal of Medical Sciences, 2020, 17, 1315-1319.	2.5	4
28	Role of long non-coding RNAs in Down syndrome patients: a transcriptome analysis study. Human Cell, 2021, 34, 1662-1670.	2.7	4
29	SPANX-B and SPANX-C (Xq27 region) gene dosage analysis in Down's syndrome subjects with undescended testes. Journal of Genetics, 2009, 88, 93-97.	0.7	3
30	Expression of LDOC1 mRNA in leucocytes of patients with Down's syndrome. Journal of Genetics, 2012, 91, 95-98.	0.7	3
31	CASP3 protein expression by flow cytometry in Down's syndrome subjects. Human Cell, 2014, 27, 43-45.	2.7	2
32	Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome. Menopause, 2016, 23, 1247-1251.	2.0	2
33	A polymorphism (rs1042522) in TP53 gene is a risk factor for Down Syndrome in Sicilian mothers. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 2752-2754.	1.5	2
34	Study of the MDM2 -410T-G polymorphism (rs2279744) by pyrosequencing in mothers of Down Syndrome subjects. Human Cell, 2020, 33, 476-478.	2.7	2
35	Poly (ADP-ribose) polymerase 1 expression in fibroblasts of Down syndrome subjects. Open Medicine (Poland), 2013, 8, 762-765.	1.3	0
36	LDOC1 expression in fibroblasts of patients with Down syndrome. Open Life Sciences, 2015, 10, .	1.4	0

#	Article	IF	CITATIONS
37	Expression of miR-132 in Down syndrome subjects. Human Cell, 2018, 31, 268-270.	2.7	O